Stay updated on the latest developments in the GLP-1 drug class, including a new generic entering the market, weight loss results, FDA decisions & cost issues.

The US Food and Drug Administration has approved the first generic referencing Victoza (liraglutide; Hikma Pharmaceuticals), ...

We recently compiled a list of the U.K. Dividend Aristocrats List: 2024 Rankings by Yield. In this article, we are going to ...

Shares of Hikma Pharmaceuticals PLC HIK inched down 0.35% to £19.82 Friday, on what proved to be an all-around favorable ...

The generic of Victoza, developed by the U.K.'s Hikma Pharmaceuticals, is set to be launched across the United States by the ...

The ongoing shortage of liraglutide injection and other GLP-1 medications prompted the FDA to prioritize the generic drug applications for these medications in order to improve patient access.

The U.S. Food and Drug Administration has approved the first generic version of Victoza (liraglutide injection), ...

The global dyspnea treatment market, valued at USD 6.31 billion in 2023, is poised for remarkable growth, with projections ...

Liraglutide injection is now approved for adult and pediatric patients ages 10 and up, proving another option amid the GLP-1 ...

Today, the U.S. Food and Drug Administration approved the first generic referencing Victoza (liraglutide injection) 18 ...

Shares of Hikma Pharmaceuticals PLC HIK inched up 0.05% to £19.89 Tuesday, on what proved to be an all-around great trading ...

AstraZeneca has voluntarily withdrawn its marketing authorisation application with the EU's medicines regulator for its ...